Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Principles of Cancer Biology and Therapy Prof Dr Solange Peters, MD, PhD Cancer Center Lausanne Switzerland Cancer is an umbrella term covering a plethora of conditions characterized by unscheduled and uncontrolled cellular proliferation • Almost any mammalian organ and cell type can succumb to oncogenic transformation • The causes of cancer are many and varied, and include genetic predisposition, environmental influences, infectious agents and ageing • Transformation occurs by derailing a wide spectrum of effector pathways. Cancer complexity is what hampered the development of effective and specific cancer therapies Cancer and Age Breast ALL Colon Testicular CNS NCCC 1988 - 2004 Cancer is a disease of extraordinary diversity In terms of • cell types of origin • organ sites Nomenclature • Benign – “Polyp” • Malignant – Epithelial • Carcinoma – Mesenchyme • Sarcoma – Hematopoietic • Leukemia • Lymphoma • Myeloma Cancer is a disease of extraordinary diversity In terms of •cell types of origin •organ sites •etiology Etiology • Systemic predisposition – Inherited cancer syndromes • p53, BRCA1 and 2, MMR – Immune deficiency syndromes • Inherited/Congenital or acquired • Exposure – Radiation (cosmic, fallout, radon) – Chemotherapy (MDS) – Viruses and bacteria • EBV, HTLV-I/II, HIV, H. pylori – Repeated injury (Acid reflux, hepatitis) • We show that the lifetime risk of cancers of many different types is strongly correlated (0.81) with the total number of divisions of the normal self-renewing cells maintaining that tissue’s homeostasis. • These results suggest that only a third of the variation in cancer risk among tissues is attributable to environmental factors or inherited predispositions. The majority is due to bad luck (…). Tomassetti&Vogelstein,Science2015 Mutationsfrequencyvariesaccordingto cancertype Comprehensive catalogue of cancer genes throgh somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types LawrenceMS,etal.Nature.2013. Melanomasandlung tumorsdisplaymany moremutationsthanaverage,with~200 nonsynonymous mutationspertumor. Theselargernumbers reflecttheinvolvement ofpotentmutagens.Accordingly, lung cancers fromsmokers have10timesasmanysomatic mutationsasthosefrom nonsmokers. Vogelstein,Science2013 Karyotypedifferencesbetweenanormal andcancercell Everycancergenomeisuniquely alteredfromitshostnormalgenome “Happyfamiliesareallalike;everyunhappy familyisunhappyinitsownway”. LeoTolstoy,AnnaKarenina Normalhumangenomesareall(mostly)alike;every cancergenomeisabnormalinitsownway. Eachcancergenomehasauniquesetofgenome alterationsfromitsnormalhost Thesealterations,however,arenotrandombutactin commonpathwaysandmechanisms MattMeyerson WE have been studying “oncogenes” • Oncogenes – myc, ras, src, abl, bcl2 • Tumor suppressor genes – p53, Rb, APC, MEN1, NF1 • MicroRNA – Transcriptome control The paradigm of drivers alterations: lung adenocarcinoma Definition of drivers? Inducible expression of mutated HER2 (HER2YVMA): Rapid development/maintenance of adenosquamous lung tumors in mice Cre-mediated activation in lung indicate that (V600E)BRAF mutation can drive tumour initiation and that its primary effect is to induce high levels of cyclin D1mediated cell proliferation Perera, PNAS 2009 Who to molecularely assess by targeted testing, evidence-based? • NSCLC adeno EGFRm, ALKr, RETr, ROSr, HER2m, HER2a, BRAFm; METm, METa • Melanoma BRAFm, (NRASm, KITm (a)?) • Colorectal KRASm, NRASm, BRAFm • GIST KITm, PDGFRαm • Glioblastoma: MGMTmethyl • Breast: HER2a, ERe, PRe • Dermatofibrosarcoma: PDGFRβr • Stomach: HER2a Cancer is a disease of extraordinary diversity In terms of •cell types of origin •organ sites •etiology • systemic predisposition • exposure • oncogenes •pathological effects on the body •rate of progression and survival •response to particular therapies The Hallmarks of Cancer Hanahan & Weinberg (2011) Cell; Hanahan & Coussens (2012) Cancer Cell Hallmarks as a cancer principle of organization Hanahan & Weinberg (2000, 2011) Definition of Hallmarks of Cancer The hallmarks are acquired functional capabilities, that allow tumors to: Perform actions (functions) • do so chronically • coopting and corrupting otherwise carefully orchestrated actions of cells and organs in the body First Hallmark of Cancer The accelerator; full speed ahead; signals for cells to to grow and divide with abandon Second Hallmark of Cancer The brakes have failed; signals to STOP are lost Third Hallmark of Cancer Avoiding assisted suicide of outlaw cells; Loss of the inborn willingness of cells to die for the benefit of the organism The fourth hallmark Circumventing a counting mechanism that prevents continued cell division when a limit is reached The fifth hallmark Turning on new blood vessel growth, to feed and nurture the growing mass of cancer cells The sixth hallmark Cancer cells grow by migrating and invading into normal organs locally and throughout the body And, in 2011, two emerging hallmarks And, in 2011, two emerging hallmarks Immune Surveillance of Tumours Sir Macfarlane Burnet, 1964 “…in animals, …, inheritable genetic changes must be common in somatic cells and a proportion of these changes will represent a step toward malignancy. It is an evolutionary necessity that there should be some mechanism for eliminating or inactivating such potentially dangerous mutant cells and it is postulated that this mechanism is of immunological character.” How are these hallmark capabilities acquired? Via Enabling Characteristics Enabling Characteristics are not functional capabilities per se, i.e. they are not actions performed by cancer cells and cancerous lesions Rather, Enabling Characteristics are consequential effects, things that have happened to cancer cells and incipient lesions that facilitate acquisition of the hallmark capabilities Two enabling characteristics for acquiring hallmarks The loss of mechanisms that maintain integrity of the genome, resulting in appearance of (rare) mutations Two enabling characteristics for acquiring hallmarks Proliferative nests of cancer cells attract an inflammatory response by the immune system Inflammation that inadvertently includes immune cells that misdiagnose the lesion as a wound to be healed, and thereby assist in hallmark capabilities Tumors are complex association of cell types similar to an individual “organ” Tumors are composed of an assemblage of cell types that communicate and collaborate Tumors are composed of an assemblage of cell types that communicate and collaborate Cancer Cell (CC) Invasive Cancer Cell Tumors are composed of an assemblage of cell types that communicate and collaborate Cancer Stem Cell (CSC) Cancer Cell (CC) Invasive Cancer Cell Tumors are composed of an assemblage of cell types that communicate and collaborate Cancer Stem Cell (CSC) Cancer Cell (CC) Endothelial Cell (EC) Invasive Cancer Cell Tumors are composed of an assemblage of cell types that communicate and collaborate Cancer Stem Cell (CSC) Cancer Cell (CC) Endothelial Cell (EC) Pericyte (PC) Invasive Cancer Cell Tumors are composed of an assemblage of cell types that communicate and collaborate Cancer Stem Cell (CSC) Cancer-Associated Fibroblast (CAF) Cancer Cell (CC) Endothelial Cell (EC) Pericyte (PC) Invasive Cancer Cell Tumors are composed of an assemblage of cell types that communicate and collaborate Cancer Stem Cell (CSC) Cancer-Associated Fibroblast (CAF) Cancer Cell (CC) Tumor-Promoting Inflammatory Cells (TPIC) Endothelial Cell (EC) Pericyte (PC) Invasive Cancer Cell Multiple normal cell types are recruited to be components of tumors, helping to provide hallmark capabilities Cancer Stem Cell (CSC) Cancer-Associated Fibroblast (CAF) Cancer Cell (CC) Tumor-Promoting Inflammatory Cells (TPIC) Endothelial Cell (EC) Pericyte (PC) Invasive Cancer Cell Stromal cells functionally contribute to 7 of 8 hallmarks Hanahan & Coussens (2012) Cancer Cell Hallmarks : Applications to Cancer Medicine? Remarkable responses in patients with metastatic melanoma treated with the B-Raf inhibitor vemurafenib Finn et al BMC Medicine 2012 Remarkable, but often transitory responses in patients with metastatic melanoma treated with the B-Raf inhibitor vemurafenib Finn et al BMC Medicine 2012 Remarkable responses in patients with metastatic NSCLC treated with the ALK inhibitor crizotinib Median PFS is ~8 – 10 months Emergence of resistant clonogens Pre-crizotinib 2 months on crizotinib Targeting individual hallmark capabilities is not working so well (EGFR, ALK, BRAF, anti-angiogenesis) What about hitting individual hallmarks at multiple nodes? 2012 Maybe by co-targeting multiple hallmarks, it will be difficult for tumors to adapt, resulting in more enduring responses ? B-Raf inhibitor Additional complexity Changes in Clonal Composition over Time Aparicio S, Caldas C. N Engl J Med 2013;368:842-851 Cortesy of Charles Swanton Phylogenetic trees of the patient's tumor over the course of therapy. Crispin T. Hiley, and Charles Swanton Cancer Discov 2016;6:122-124 Fig. 1 Heterogeneity and prognostic value of neoantigen landscape in primary NSCLC. Nicholas McGranahan et al. Science 2016;science.aaf1490 Published by AAAS Thanks to Doug Hanahan Thanks for your attention